O Uso Terapêutico da Psilocibina em Pacientes com Câncer Terminal: Eficácia, Eficiêcia e Bem-Estar.
Palavras-chave:
Psilocibina; Câncer Terminal; Terapia Psicodélica; Bem-Estar Psicológico; Cuidados PaliativosResumo
Este estudo investigou o impacto terapêutico da psilocibina em pacientes com câncer terminal, através da compilação dos resultados de três ensaios clínicos que usaram psilocibina no tratamento de pessoas com câncer terminal, visando reduzir sintomas de depressão, ansiedade e estresse existencial., Utilizaram-se métodos observacionais e analíticos, incluindo entrevistas e escalas de avaliação. Os resultados evidenciaram melhorias significativas nos sintomas logo após a administração de psilocibina, mantendo-se a longo prazo. Os pacientes relataram melhora na qualidade de vida, bem-estar espiritual e satisfação com o tratamento, com efeitos adversos mínimos. Conclui-se que a psilocibina tem potencial terapêutico no alívio de sintomas psicológicos em pacientes terminais, sugerindo seu uso como complemento nos cuidados paliativos. São dois os principais polos de pesquisa com psilocibina no mundo: Dr. Roland R. Griffiths, na Johns Hopkins University School of Medicine e Dr. Stephen Ross, da Escola de Medicina da Universidade de Nova York.
Referências
⦁ Savage, C., Smith, D. H., & Beaton, J. M. (1952). Lysergic Acid Diethylamide (LSD-25): IV. A Comparison of the Effects of Different Amounts. Journal of Mental Science, 98(412), 95–103.
⦁ Bastiaans, J., Koele, P., & Oderwald, A. (1961-1988). The use of LSD in the psychotherapy of neuroses. Journal of Psychoactive Drugs, 23(6), 641–648.
⦁ Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2018). Effects of Ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology, 219, 21–27. DOI: 10.1016/j.jep.2017.10.032
⦁ Ross, S. (2017). Psychedelics and death: A survey of the literature. Social Research, 84(4), 951–981.
⦁ Stijve, T., & Kuyper, T. W. (1995). Occurrence of psilocybin in various higher fungi from several European countries. Planta Medica, 61(5), 423–426.
⦁ Montenegro, G. (2006). The ritual use of ayahuasca by three Brazilian religions. In T. B. Roberts, & D. Jesse (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness (Vol. 5, pp. 113–174). Verlag, Synergetics.
⦁ Melo, R. (2011). Santo Daime: Perfil das lideranças da Barquinha. Ponto Urbe, 9(10). DOI: 10.4000/pontourbe.2359
⦁ Vicentini, A. (2021). The use of ayahuasca in a Brazilian religious institution: A behavioral economic analysis. Substance Use & Misuse, 56(4), 534–543. DOI: 10.1080/10826084.2020.1838289
⦁ Vorobyeva, N., & Kozlova, A. A. (2022). Psychedelic 5-HT2A receptor agonists and their potential for therapeutic applications: A systematic review. Journal of Psychoactive Drugs, 54(1), 1–15. DOI: 10.1080/02791072.2021.2032894
⦁ Isbell, H. (1959). Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia, 1(1), 29–38.
⦁ Grob, C. S., Bossis, A. P., Griffiths, R. R., & Danforth, A. L. (2011). Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In S. W. Ross (Ed.), Psilocybin and the Knowledge of Death (pp. 149–162). MAPS.
⦁ Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2016). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. DOI: 10.1007/s00213-011-2358-5
⦁ Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., & Su, Z. (2021). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 35(1), 189–199. DOI: 10.1177/02698811211007269
⦁ Conforto, D. (2011). Metodologia Científica. Atheneu.Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. European Journal of Epidemiology. 2020;35(1):49-60.
⦁ Studerus E, Gamma A, Kometer M, Vollenweider FX. Hallucinogen Persisting Perception Disorder: Diagnostic Criteria, Clinical Aspects, and Therapeutic Perspectives. Journal of Psychopharmacology. 2011;25(2):160-8. DOI: 10.1177/0269881110387178.
⦁ Puchalski CM. The role of spirituality in health care. Proc (Bayl Univ Med Cent). 2012;25(4):352-7.
⦁ Doblin R. Pahnke's "Good Friday experiment": a long-term follow-up and methodological critique. J Transpersonal Psychol. 1991;23(1):1-28.
⦁ Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-83.
⦁ Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649-65.
⦁ Pahnke WN. Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Harv Theol Rev. 1963;56(3):199-233.
⦁ Savage, C., Smith, D. H., & Beaton, J. M. (1952). Lysergic Acid Diethylamide (LSD-25): IV. A Comparison of the Effects of Different Amounts. Journal of Mental Science, 98(412), 95–103.
⦁ Bastiaans, J., Koele, P., & Oderwald, A. (1961-1988). The use of LSD in the psychotherapy of neuroses. Journal of Psychoactive Drugs, 23(6), 641–648.
⦁ Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2018). Effects of Ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology, 219, 21–27. DOI: 10.1016/j.jep.2017.10.032
⦁ Ross, S. (2017). Psychedelics and death: A survey of the literature. Social Research, 84(4), 951–981.
⦁ Stijve, T., & Kuyper, T. W. (1995). Occurrence of psilocybin in various higher fungi from several European countries. Planta Medica, 61(5), 423–426.
⦁ Montenegro, G. (2006). The ritual use of ayahuasca by three Brazilian religions. In T. B. Roberts, & D. Jesse (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness (Vol. 5, pp. 113–174). Verlag, Synergetics.
⦁ Melo, R. (2011). Santo Daime: Perfil das lideranças da Barquinha. Ponto Urbe, 9(10). DOI: 10.4000/pontourbe.2359
⦁ Vicentini, A. (2021). The use of ayahuasca in a Brazilian religious institution: A behavioral economic analysis. Substance Use & Misuse, 56(4), 534–543. DOI: 10.1080/10826084.2020.1838289
⦁ Vorobyeva, N., & Kozlova, A. A. (2022). Psychedelic 5-HT2A receptor agonists and their potential for therapeutic applications: A systematic review. Journal of Psychoactive Drugs, 54(1), 1–15. DOI: 10.1080/02791072.2021.2032894
⦁ Isbell, H. (1959). Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia, 1(1), 29–38.
⦁ Grob, C. S., Bossis, A. P., Griffiths, R. R., & Danforth, A. L. (2011). Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In S. W. Ross (Ed.), Psilocybin and the Knowledge of Death (pp. 149–162). MAPS.
⦁ Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2016). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. DOI: 10.1007/s00213-011-2358-5
⦁ Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., & Su, Z. (2021). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 35(1), 189–199. DOI: 10.1177/02698811211007269
Downloads
Publicado
Como Citar
Edição
Seção
Categorias
Licença
Copyright (c) 2025 MOEMA DE CASTRO, Di Medeiros Leal, M, C., Alexandre Pereira dos Santos, Letícia Mylena Guedes Rocha
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Esta obra esta licenciada sob uma Licença Creative Commons. Os usuários têm permissão para copiar redistribuir os trabalhos por qualquer meio ou formato, e também para, tendo como base o seu conteúdo, reutilizar, transformar ou criar, com, propositos legais, até comerciais, desde que citada a fonte.
